Devgen - direct/ Devgen (BE) - Devgen and Sumitomo advertise addendum of crop aegis collaboration

Zwijnaarde, 22 June 2006 - Devgen (Euronext Brussels: DEVG) today appear that it has active a two-year addendum of the analysis accord with Sumitomo Chemical Company Limited to advance atypical insecticides.

In the collaboration, Devgen selects and validates atypical insecticidal targets, formats top throughput assays and uses its ability in computational allure to bear insect breath leads, which Sumitomo added develops into marketed products. Under the agreement of the agreement, Devgen receives analysis allotment and is acceptable for milestones and royalties.

"The addendum of the analysis accord follows the acknowledged clue we accept accordingly followed back 2001. We were afflicted with the actual after-effects Devgen delivered and we are analytic advanced to alive calm for the next two years", said Dr. Ogawa, General Manager of Sumitomo´s Agricultural Chemicals Sector.

"Starting from the alternative of atypical annoyance specific targets enables the development of insecticides that act through a altered apparatus of action and that are added environmentally friendly, compared to articles already on the market", said Devgen´s CEO, Dr. Thierry Bogaert. "We are actual admiring to abide to use our beat technologies to accord to Sumitomo´s analysis and development of insecticidal compounds."

About Sumitomo Chemical
Sumitomo Chemical is a Japan-based actinic and biologic aggregation that operates through a arrangement of subsidiaries, affiliates and communication offices about the world. With anniversary sales of 12 billion U.S. dollars, it seeks to be a all-around baton in the actinic industry in the 21st century. Life Sciences is one of the three antecedence areas that Sumitomo Chemical has articular for accomplishing abiding growth.

About Devgen
Devgen is an innovator in biotechnology focused on discovering, developing and commercializing:

- a atypical bearing of biotech articles to assure a advanced spectrum of crops from accident incurred from pests;

- safer and added environmentally affable agro-chemical articles to assure crops from accident inflicted by bulb abject nematodes;

- atypical ameliorative concepts and preclinical biologic candidates for analysis of metabolic ache (diabetes, obesity, arrhythmia).

Each of these solutions is developed on a belvedere of centralized advised research, development programs and technologies. Devgen has partnerships with industry leaders such as Monsanto, DuPont/Pioneer, and Sumitomo.
Incorporated in 1997, Devgen has offices in Ghent (Belgium) and Singapore - with a absolute workforce of over 100 people.

www.devgen.com



For added information, amuse contact:

Hilde Windels, CFO
+32 9 324 24 24
hlde.windels@devgen.com


Devgen columnist absolution EN




The advertisement broadcast by directnews.